Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Jeongmin Lee, Seung-Hwan Lee
Korean J Intern Med. 2023;38(6):797-809. Published online October 20, 2023
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging to achieve optimal LDL-C goals with statin monotherapy. Ezetim..
|
|
Cardiology
Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry
Han Joon Bae, Yun-Kyeong Cho, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Seongwook Han, Seung-Ho Hur, Yoon-Nyun Kim, Kwon-Bae Kim, Jae-Kean Ryu, Deug Young Nah, Chang-Wook Nam
Korean J Intern Med. 2020;35(2):342-350. Published online August 19, 2019
Background/Aims: To date, prospective data are limited on efficacy and safety profiles of statin therapy in Korean hypercholesterolemic patients. Hence, the aim of this study was to evaluate the practice patterns of statin therapy and its efficacy and safety through the prospective Daegu and Gyeong..
|
|
Endocrinology-metabolism
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
Da Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung-Il Kim, Byeong Woo Park, Yumie Rhee
Korean J Intern Med. 2019;34(3):579-587. Published online August 25, 2017
Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have sh..
|
|
The Contribution of Abdominal Obesity and Dyslipidemia to Metabolic Syndrome in Psychiatric Patients
Sung-Hwan Kim, Kiwon Kim, Mi Hyang Kwak, Hak Jin Kim, Hong-Sup Kim, Ki Hoon Han
Korean J Intern Med. 2010;25(2):168-173. Published online June 1, 2010
Background/AimsMetabolic syndrome is an emerging risk factor for cardiovascular disease. This study investigated the prevalence of metabolic syndrome among psychiatric patients in order to identify the dominant factors of metabolic syndrome. Methods
|
|
The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
Hye Eun Yoon, Joon Chang Song, Bok Jin Hyoung, Hyeon Seok Hwang, So Young Lee, Youn Joo Jeon, Bum Soon Choi, Yong Soo Kim, Chul Woo Yang
Korean J Intern Med. 2009;24(3):233-237. Published online August 26, 2009
Background/AimsThe efficacy and safety of a combination of ezetimibe and low-dose statin as primary treatment for dyslipidemia in renal transplant patients were evaluated prospectively. MethodsThe study enrolled 77 renal transplant recipients wi..
|
|
|